Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

Fig. 3

Relationship between Ctrough and episodic memory measures. Plasma trough drug concentration in neflamapimod versus change from baseline to week 24. a HVLT-R combined total and delayed recall Z-score (i.e., primary endpoint), and b WMS combined immediate and delayed recall composite is shown in circles (open for treatment-naïve subjects, closed for those on background AD therapy). For comparison, placebo subjects are shown in triangles (open for treatment-naïve subjects, closed for those on background AD therapy) on the left side of the figure

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193